Lariphan acquire a biotechnological way from E. coli bacteria after infection with bacteriophage. Lariphan is the original product, developed in the second half of last century, Latvian ZA Microbiology Institute (now - RSU Microbiology and Virology Institute). Lariphan biological properties also participated in research leading Soviet scientific institutes in Moscow, Leningrad, Kiev, etc. Lariphan production since 1997 happens Ltd. "Larifans" the factory in Riga.
Experimental studies (non-clinical) and the data collected during clinical trials, show that Lariphan is interferon (IFN) inducer, and the resulting biological effects can be both induced endogenous interferon and dsRNA molecules direct the outcome. Lariphan has pleiotropic biological activities, such as the ability to induce interferon, the occurrence of antiviral, immunomodulatory, antineoplastic, and antimutagēnus effects.
Lariphan interferoninducējošā activity demonstrated in both humans and various species of animals. Lariphan as well as interferon may be considered as a universal antiviral, as it ceases to viral replication phases, which are common to all viruses.
Lariphan antiviral effect as detected in vitro, whereas in vivo. Tissue culture and animal experiments Lariphan hampered viral reproduction and infection process of herpes, influenza, tick-borne encephalitis, encephalomyocarditis, Semiliki, Sindbis, Venezuelan encephalitis, Aujeszkys, rabies and other viral infections. Displaying Lariphan dampening effect on the progress of experimental chlamydial infection mice. Antitumorāli effects demonstrated in various experimental tumor models, as well as the preliminary study clinic.
Demonstrated immunomodulatory activity as at the local and parenteral Lariphan application. Locally applied Lariphan causing localized lymphocytosis and NK cell numbers increase. Lariphan injections activates macrophages, stimulates the fagocitāro activity, strengthening the NK activity, increase of active T-cells, induces T-ly citocidālo activity, acting as an Adjuvant use in combination with a specific vaccine, lowers late hypersensitivity. Specific systems observed Lariphan antimutagena activity. Clinical trials found that Lariphan does not have carcinogenic, mutagenic, irritant and topical alerģizējošas activity.
About Lariphan the clinical effectiveness of the observations, obtained using the injection form Lariphan, as well as the many years of experience Lariphan ointment use. Larifans injections verified the clinic as an antiviral preparation at the tick-borne encephalitis, and herpes virus infections, and as Immunomodulating agent at a secondary immunodeficiency and oncological patients. In the preliminary study carried out using Larifanu candles have shown that the preparation is active in the so-called sexually transmitted infections - the herpes, papilloma (condyloma acuminata) caused by viral infections, as well as in combination with antibiotics gives a good therapeutic effect of chlamydial infection cases. Lariphan svecīšu clinical studies showed therapeutic effect in patients with recurrent herpes infection.
Clinical preliminary data provide some information about Lariphan tolerability and safety. Larifans injections proved safe and well tolerated. Lariphan greases and Lariphan svecīšu clinical trial period adverse side effects were reported.
There are a number of Lariphan formulation. Lariphan form of ointment (0.05% Lariphan ointment) since 1994, entered the National Register of Medicinal Products as an antiviral agent and re-up to 2004. Lariphan injection form established in 2004 as Immunomodulating agent, and its sales network of pharmacies has been conducted since 2005. By Lariphan svecīšu form 2003. was opened (but still not completed), clinical trials at the recurrent herpes virus infections.
Lariphan prophylactic doses include various cosmetic products. Pharmacy Network is a distributed Balzāms Lariphan lips and teeth Lariphan mail. In preparation for registration is 0025% Lariphan ointment and spray in mouth.
The product group of medical products are registered and distributed in pharmacies Lariphan containing rectal (3 different doses) and pesāriji. Lariphan active substance manufacturer and Larifans Ltd., dsLarifans acquisition technique patented in 1993 in Latvia.
Experimental studies (non-clinical) and the data collected during clinical trials, show that Lariphan is interferon (IFN) inducer, and the resulting biological effects can be both induced endogenous interferon and dsRNA molecules direct the outcome. Lariphan has pleiotropic biological activities, such as the ability to induce interferon, the occurrence of antiviral, immunomodulatory, antineoplastic, and antimutagēnus effects.
Lariphan interferoninducējošā activity demonstrated in both humans and various species of animals. Lariphan as well as interferon may be considered as a universal antiviral, as it ceases to viral replication phases, which are common to all viruses.
Lariphan antiviral effect as detected in vitro, whereas in vivo. Tissue culture and animal experiments Lariphan hampered viral reproduction and infection process of herpes, influenza, tick-borne encephalitis, encephalomyocarditis, Semiliki, Sindbis, Venezuelan encephalitis, Aujeszkys, rabies and other viral infections. Displaying Lariphan dampening effect on the progress of experimental chlamydial infection mice. Antitumorāli effects demonstrated in various experimental tumor models, as well as the preliminary study clinic.
Demonstrated immunomodulatory activity as at the local and parenteral Lariphan application. Locally applied Lariphan causing localized lymphocytosis and NK cell numbers increase. Lariphan injections activates macrophages, stimulates the fagocitāro activity, strengthening the NK activity, increase of active T-cells, induces T-ly citocidālo activity, acting as an Adjuvant use in combination with a specific vaccine, lowers late hypersensitivity. Specific systems observed Lariphan antimutagena activity. Clinical trials found that Lariphan does not have carcinogenic, mutagenic, irritant and topical alerģizējošas activity.
About Lariphan the clinical effectiveness of the observations, obtained using the injection form Lariphan, as well as the many years of experience Lariphan ointment use. Larifans injections verified the clinic as an antiviral preparation at the tick-borne encephalitis, and herpes virus infections, and as Immunomodulating agent at a secondary immunodeficiency and oncological patients. In the preliminary study carried out using Larifanu candles have shown that the preparation is active in the so-called sexually transmitted infections - the herpes, papilloma (condyloma acuminata) caused by viral infections, as well as in combination with antibiotics gives a good therapeutic effect of chlamydial infection cases. Lariphan svecīšu clinical studies showed therapeutic effect in patients with recurrent herpes infection.
Clinical preliminary data provide some information about Lariphan tolerability and safety. Larifans injections proved safe and well tolerated. Lariphan greases and Lariphan svecīšu clinical trial period adverse side effects were reported.
There are a number of Lariphan formulation. Lariphan form of ointment (0.05% Lariphan ointment) since 1994, entered the National Register of Medicinal Products as an antiviral agent and re-up to 2004. Lariphan injection form established in 2004 as Immunomodulating agent, and its sales network of pharmacies has been conducted since 2005. By Lariphan svecīšu form 2003. was opened (but still not completed), clinical trials at the recurrent herpes virus infections.
Lariphan prophylactic doses include various cosmetic products. Pharmacy Network is a distributed Balzāms Lariphan lips and teeth Lariphan mail. In preparation for registration is 0025% Lariphan ointment and spray in mouth.
The product group of medical products are registered and distributed in pharmacies Lariphan containing rectal (3 different doses) and pesāriji. Lariphan active substance manufacturer and Larifans Ltd., dsLarifans acquisition technique patented in 1993 in Latvia.
